[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PT2707101T - Reguladores da proteostase - Google Patents

Reguladores da proteostase

Info

Publication number
PT2707101T
PT2707101T PT12781736T PT12781736T PT2707101T PT 2707101 T PT2707101 T PT 2707101T PT 12781736 T PT12781736 T PT 12781736T PT 12781736 T PT12781736 T PT 12781736T PT 2707101 T PT2707101 T PT 2707101T
Authority
PT
Portugal
Prior art keywords
proteostasis regulators
proteostasis
regulators
Prior art date
Application number
PT12781736T
Other languages
English (en)
Inventor
Foley Megan
Tait Bradley
Cullen Matthew
Original Assignee
Proteostasis Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proteostasis Therapeutics Inc filed Critical Proteostasis Therapeutics Inc
Publication of PT2707101T publication Critical patent/PT2707101T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/333—Radicals substituted by oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/337—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/22—Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
PT12781736T 2011-05-12 2012-05-10 Reguladores da proteostase PT2707101T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161485421P 2011-05-12 2011-05-12

Publications (1)

Publication Number Publication Date
PT2707101T true PT2707101T (pt) 2019-05-30

Family

ID=47139667

Family Applications (1)

Application Number Title Priority Date Filing Date
PT12781736T PT2707101T (pt) 2011-05-12 2012-05-10 Reguladores da proteostase

Country Status (18)

Country Link
US (3) US9556166B2 (pt)
EP (2) EP3552664A1 (pt)
JP (1) JP6208122B2 (pt)
CN (1) CN103635230B (pt)
AU (2) AU2012253402A1 (pt)
CA (1) CA2835610C (pt)
CY (1) CY1121985T1 (pt)
DK (1) DK2707101T3 (pt)
ES (1) ES2724531T3 (pt)
HR (1) HRP20190867T1 (pt)
HU (1) HUE044867T2 (pt)
LT (1) LT2707101T (pt)
PL (1) PL2707101T3 (pt)
PT (1) PT2707101T (pt)
RS (1) RS58718B1 (pt)
SI (1) SI2707101T1 (pt)
TR (1) TR201906779T4 (pt)
WO (1) WO2012154967A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011210765A1 (en) 2010-01-28 2012-09-13 President And Fellows Of Harvard College Compositions and methods for enhancing proteasome activity
WO2012154967A1 (en) 2011-05-12 2012-11-15 Proteostasis Therapeutics, Inc. Proteostasis regulators
US9849135B2 (en) 2013-01-25 2017-12-26 President And Fellows Of Harvard College USP14 inhibitors for treating or preventing viral infections
WO2015073528A1 (en) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
RU2020134082A (ru) 2014-10-06 2020-11-27 Вертекс Фармасьютикалз Инкорпорейтед Модуляторы регулятора трансмембранной проводимости при муковисцидозе
PT3210973T (pt) 2014-10-24 2021-02-12 Takeda Pharmaceuticals Co Compostos de heteroarilo para o tratamento de doenças oftálmicas
CN104478780B (zh) * 2014-11-17 2017-04-19 华东师范大学 酰基吡咯类小分子有机化合物及其衍生物、用途及其制备方法
AU2017275657B2 (en) 2016-06-02 2021-08-19 Novartis Ag Potassium channel modulators
PT3571193T (pt) 2017-01-23 2022-03-25 Cadent Therapeutics Inc Moduladores dos canais de potássio
CA3103954A1 (en) 2018-06-27 2020-01-02 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
WO2020006269A1 (en) * 2018-06-27 2020-01-02 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
AU2019344897B2 (en) 2018-09-18 2024-01-18 Nikang Therapeutics, Inc. Tri-substituted heteroaryl derivatives AS SRC homology-2 phosphatase inhibitors
MX2021004647A (es) 2018-10-22 2021-08-16 Novartis Ag Formas cristalinas de moduladores de los canales de potasio.
BR112021019817A2 (pt) 2019-04-03 2021-12-07 Aligos Therapeutics Inc Compostos de pirrol

Family Cites Families (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1073521A (en) 1963-03-20 1967-06-28 Benger Lab Ltd Indole derivatives
GB1410783A (en) 1972-01-20 1975-10-22 Wyeth John & Brother Ltd N-substituted 4-amidopyridines tetrahydropyridines and piperidines
DE2557341A1 (de) 1975-12-19 1977-06-30 Hoechst Ag Basisch substituierte indolderivate und verfahren zu ihrer herstellung
BR8008732A (pt) 1979-06-28 1981-04-28 Ciba Geigy Ag Estabilizadores para compostos termoplasticos clorados
HU895334D0 (en) 1986-07-30 1990-01-28 Sandoz Ag Process for the preparation of nasal pharmaceutical compositions
GB8623819D0 (en) 1986-10-03 1986-11-05 Glaxo Group Ltd Heterocyclic compounds
CA2092112A1 (en) 1992-03-23 1993-09-24 Nobuyoshi Iwata Indole and indazole derivatives, for the treatment and prophylaxis of cerebral disorders, their preparation and their use
DE4325204C2 (de) 1993-07-27 2002-11-28 Matthias Lehr Acylpyrrolalkansäuren und ihre Derivate als Hemmstoffe der Phospholipase A¶2¶
US5852046A (en) 1993-08-03 1998-12-22 Hoechst Aktiengesellschaft Benzo-fused heterocyclic compounds having a 5-membered ring processes for their preparation their use as medicaments their use as diagnostic agents and medicaments containing them
EP0639573A1 (de) 1993-08-03 1995-02-22 Hoechst Aktiengesellschaft Benzokondensierte 5-Ringheterocyclen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, ihre Verwendung als Diagnostikum, sowie sie enthaltendes Medikament
JPH07133274A (ja) 1993-11-09 1995-05-23 Sankyo Co Ltd ピロール誘導体
DE4338770A1 (de) 1993-11-12 1995-05-18 Matthias Dr Lehr Indol-2-alkansäuren und ihre Derivate als Hemmstoffe der Phospholipase A¶2¶
CZ283216B6 (cs) 1994-01-19 1998-02-18 Sankyo, Company Limited Pyrrolopyridazinové deriváty
JPH08225535A (ja) * 1994-11-15 1996-09-03 Dai Ichi Seiyaku Co Ltd インダゾール誘導体
JPH11501004A (ja) 1995-02-01 1999-01-26 ユニヴァーシティー・カレッジ・カーディフ・コンサルタンツ・リミテッド 三環系誘導体及びそれらの抗ガン剤としての使用
KR100430059B1 (ko) * 1995-04-10 2004-09-24 후지사와 야꾸힝 고교 가부시키가이샤 cGMP-PDE억제제로서의인돌유도체
US5567711A (en) 1995-04-19 1996-10-22 Abbott Laboratories Indole-3-carbonyl and indole-3-sulfonyl derivatives as platelet activating factor antagonists
JPH10508321A (ja) 1995-09-01 1998-08-18 イーライ・リリー・アンド・カンパニー インドリル神経ペプチドｙレセプターアンタゴニスト
AU717422B2 (en) * 1995-09-01 2000-03-23 Eli Lilly And Company Indolyl neuropeptide Y receptor antagonists
AU716381B2 (en) 1996-04-03 2000-02-24 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5859035A (en) 1996-04-03 1999-01-12 Merck & Co., Inc. Arylheteroaryl inhibitors of farnesyl-protein transferase
DE19622222A1 (de) 1996-06-03 1997-12-04 Hoechst Ag Verwendung von Inhibitoren des zellulären Na·+·/H·+·-Exchangers (NHE) zur Herstellung eines Medikament zur Normalisierung der Serumlipide
US20040122096A1 (en) 1996-06-03 2004-06-24 Hoechst Aktiengesellschaft Use of inhibitors of the cellular Na+/H+ exchanger (NHE) for preparing a medicament for normalizing serum lipids
ES2208935T3 (es) 1996-08-01 2004-06-16 Merckle Gmbh Acidos acil-pirrol-dicarboxilicos y acidos acil-indol-dicarboxilicos, asi como sus derivados como inhibidores de la fosfolipasa a2 citosolica.
US5998462A (en) 1996-12-16 1999-12-07 Allelix Biopharmaceuticals Inc. 5-alkyl indole compounds
EP1049483A1 (en) 1998-01-23 2000-11-08 National Jewish Medical and Research Center Method for treating inflammatory diseases using heat shock proteins
TR200002445T2 (tr) 1998-02-25 2000-12-21 Genetics Institute, Inc. Fosfolipaz inhibitörleri.
US6828344B1 (en) 1998-02-25 2004-12-07 Genetics Institute, Llc Inhibitors of phospholipase enzymes
US6500853B1 (en) 1998-02-28 2002-12-31 Genetics Institute, Llc Inhibitors of phospholipase enzymes
DE19814838C2 (de) * 1998-04-02 2001-01-18 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung
US6589954B1 (en) 1998-05-22 2003-07-08 Scios, Inc. Compounds and methods to treat cardiac failure and other disorders
US6867209B1 (en) 1998-05-22 2005-03-15 Scios, Inc. Indole-type derivatives as inhibitors of p38 kinase
AUPP433398A0 (en) 1998-06-25 1998-07-16 Australian National University, The Compounds and processes
JP2000063354A (ja) 1998-08-21 2000-02-29 Sumitomo Pharmaceut Co Ltd ピロール誘導体
US6358992B1 (en) * 1998-11-25 2002-03-19 Cell Pathways, Inc. Method of inhibiting neoplastic cells with indole derivatives
US6469006B1 (en) 1999-06-15 2002-10-22 Bristol-Myers Squibb Company Antiviral indoleoxoacetyl piperazine derivatives
JP2001151771A (ja) 1999-09-10 2001-06-05 Kyowa Hakko Kogyo Co Ltd 含窒素芳香族複素環誘導体
AU2252101A (en) 1999-12-16 2001-06-25 Eli Lilly And Company New synthesis of SPLA2 inhibitors
AU4316301A (en) * 2000-03-14 2001-10-08 Upjohn Co Novel 2,3,4,5-tetrahydro-1H-(1,4)diazepino(1,7a)indole compounds
NZ521978A (en) 2000-04-28 2004-10-29 Acadia Pharm Inc Compounds that affect cholinergic receptors and are particularly muscarinic agonists
JPWO2002000621A1 (ja) * 2000-06-29 2004-04-22 塩野義製薬株式会社 Ｘ型ｓＰＬＡ２阻害作用を有する化合物
ES2172415B2 (es) 2000-07-28 2003-11-16 Univ Madrid Complutense Tratamiento del glaucoma y la hipertension ocular por medio de un analogo de la melatonina.
EP1377549A1 (en) 2001-03-12 2004-01-07 Millennium Pharmaceuticals, Inc. Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor
US7842470B2 (en) 2001-10-09 2010-11-30 Oregon Health & Science University Method for pharmacoperones correction of GnRHR mutant protein misfolding
JP2005511616A (ja) 2001-11-09 2005-04-28 サイオス インク． 嚢胞性繊維症を治療する方法
US20060148767A1 (en) 2001-12-06 2006-07-06 George Cioca Use of acyl salicylates as heat shock inducers
US7528165B2 (en) 2001-12-13 2009-05-05 National Health Research Institutes Indole compounds
US7632955B2 (en) 2001-12-13 2009-12-15 National Health Research Institutes Indole compounds
AU2003265681A1 (en) 2002-08-29 2004-03-19 Merck And Co., Inc. Indoles having anti-diabetic activity
JP2006511583A (ja) * 2002-12-20 2006-04-06 ファルマシア・コーポレーション マイトジェン活性化プロテインキナーゼ−活性化プロテインキナーゼ−２を阻害するための非環式ピラゾール化合物
BR122019010200B8 (pt) 2003-05-22 2021-07-27 Nerviano Medical Science S R L compostos de pirazol-quinazolina, seus sais, produtos ou kits e composições farmacêuticas
DE602004025708D1 (de) * 2003-07-11 2010-04-08 Proteologics Inc Ubiquitin-ligase-hemmer und verwandte verfahren
CA2531064C (en) 2003-07-15 2012-05-22 Dainippon Sumitomo Pharma Co., Ltd. Novel heteroaryl derivative
US7576206B2 (en) 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
WO2005024416A1 (en) 2003-09-05 2005-03-17 Binghe Wang Water soluble boronic acid fluorescent reporter compounds and methods of use thereof
US20050203063A1 (en) 2003-09-12 2005-09-15 Raymond Deshaies Proteasome pathway inhibitors and related methods
DE10348022A1 (de) * 2003-10-15 2005-05-25 Imtm Gmbh Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
ATE482211T1 (de) * 2003-10-28 2010-10-15 Sepracor Inc Imidazoä1,2-aüpyridin-anxiolytika
EP1682134A4 (en) 2003-11-12 2008-10-15 Amicus Therapeutics Inc GLUCOIMIDAZOLE AND POLYHYDROXYCYCLOHEXENYL-AMINE DERIVATIVES FOR THE TREATMENT OF GAUCHER DISEASE
TW200522944A (en) * 2003-12-23 2005-07-16 Lilly Co Eli CB1 modulator compounds
US7417063B2 (en) 2004-04-13 2008-08-26 Bristol-Myers Squibb Company Bicyclic heterocycles useful as serine protease inhibitors
GB0408772D0 (en) 2004-04-20 2004-05-26 Glaxo Group Ltd Compounds
US8197819B2 (en) 2004-06-08 2012-06-12 Novartis Vaccines And Diagnostics, Inc. Env polypeptide complexes and methods of use
WO2005123671A1 (ja) 2004-06-22 2005-12-29 Taisho Pharmaceutical Co., Ltd. ピロール誘導体
ES2246721B1 (es) 2004-08-10 2007-03-16 Laboratorios Del Dr. Esteve, S.A. Compuestos indolicos sustituidos, su preparacion y su uso como medicamentos.
US20090264384A1 (en) 2004-11-01 2009-10-22 Nuada, Inc. Indole, benzimidazole, and benzolactam boronic acid compounds, analogs thereof and methods of use thereof
US20060135540A1 (en) 2004-11-30 2006-06-22 Jack Lin PPAR active compounds
GB0500492D0 (en) 2005-01-11 2005-02-16 Cyclacel Ltd Compound
WO2006075638A1 (ja) 2005-01-14 2006-07-20 Dainippon Sumitomo Pharma Co., Ltd. 新規ヘテロアリール誘導体
WO2006087355A1 (en) 2005-02-16 2006-08-24 Solvay Pharmaceuticals B.V. 1h-imidiazole derivatives as cannabinoid cb2 receptor modulators
ES2572148T3 (es) 2005-05-17 2016-05-30 Amicus Therapeutics Inc Un método para el tratamiento de la enfermedad de Pompe usando 1-desoxinojirimicina y derivados
AU2006251832A1 (en) * 2005-05-27 2006-11-30 Queen's University At Kingston Treatment of protein folding disorders
MX2007015602A (es) 2005-06-08 2008-02-21 Amicus Therapeutics Inc Tratamiento de trastornos del sistema nervioso central asociados con mutaciones en genes que codifican las enzimas lisosomicas.
PL1904455T3 (pl) * 2005-07-05 2012-01-31 Hoffmann La Roche Pochodne pirydazyny
WO2007035620A2 (en) 2005-09-16 2007-03-29 Serenex, Inc. Carbazole derivatives
EP1783114A1 (en) 2005-11-03 2007-05-09 Novartis AG N-(hetero)aryl indole derivatives as pesticides
EP1984334B1 (en) 2006-02-15 2014-04-09 Allergan, Inc. Indole-3-carboxylic acid amide, ester, thioamide and thiol ester compounds bearing aryl or heteroaryl groups having sphingosine-1-phosphate (s1p) receptor antagonist biological activity
US20070207992A1 (en) 2006-02-21 2007-09-06 Board Of Trustees Of Michigan State University Geldanamycin derivatives and method of use thereof
US8097644B2 (en) 2006-03-28 2012-01-17 Allergan, Inc. Indole compounds having sphingosine-1-phosphate (S1P) receptor antagonist
WO2007131034A1 (en) 2006-05-03 2007-11-15 The Regents Of The University Of Michigan Pyrimidone derivatives which are modulators of heat shock protein (hsp) 70
EP2533050B3 (en) 2006-05-16 2015-06-24 Amicus Therapeutics, Inc. Treatment Options For Fabry Disease
MX2007006175A (es) 2006-05-24 2009-02-16 Amicus Therapeutics Inc Sal de tartrato de isofagomina y metodos de uso.
KR100807393B1 (ko) 2006-06-05 2008-02-28 경상대학교산학협력단 Ｔｉ－Ｎｉ계 경사기능 합금의 제조방법 및 그로부터제조된 Ｔｉ－Ｎｉ계 경사기능 합금
DK2040548T3 (da) 2006-06-23 2012-08-13 Amicus Therapeutics Inc Fremgangsmåde til behandling af neurologiske forstyrrelser ved forøgelse af aktiviteten af beta-glucocerebrosidase
WO2008019139A2 (en) 2006-08-04 2008-02-14 Beth Israel Deaconess Medical Center Inhibitors of pyruvate kinase and methods of treating disease
EP2610244A1 (en) 2006-08-07 2013-07-03 Ironwood Pharmaceuticals, Inc. Indole compounds
WO2008024978A2 (en) 2006-08-24 2008-02-28 Serenex, Inc. Tetrahydroindolone and tetrahydroindazolone derivatives
EP1902733A1 (en) 2006-09-19 2008-03-26 Laboratorios Del Dr. Esteve, S.A. Combination of a NMDA-receptor ligand and a compound with 5-HT6 receptor affinity
EP2113500A1 (en) 2006-10-31 2009-11-04 Takeda Pharmaceutical Company Limited MAPK/ERK kinase inhibitors
US8524917B2 (en) 2007-01-11 2013-09-03 Allergan, Inc. 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity
JP2010518025A (ja) 2007-02-05 2010-05-27 アミラ ファーマシューティカルス，インコーポレーテッド ５−リポキシゲナーゼ活性化タンパク質（ｆｌａｐ）インヒビターとしての逆インドール
MX2009008439A (es) * 2007-02-12 2009-08-13 Intermune Inc Nuevos inhibidores de la replicacion del virus de hepatitis c.
ATE482209T1 (de) 2007-03-08 2010-10-15 Irm Llc Verbindungen und zusammensetzungen als modulatoren der gpr119-aktivität
CN101016294A (zh) 2007-03-13 2007-08-15 中国人民武装警察部队医学院 具有多种生物活性的取代吲哚－3－基草酰胺衍生物
CA2681979A1 (en) 2007-03-29 2008-10-09 Asubio Pharma Co., Ltd. Indole derivatives having cpla2 inhibiting activity and applications and production methods of the same
US8091582B2 (en) 2007-04-13 2012-01-10 Cla-Val Co. System and method for hydraulically managing fluid pressure downstream from a main valve between set points
CA2685017A1 (en) 2007-04-26 2008-11-06 Merck & Co., Inc. 2-substituted indole derivatives as calcium channel blockers
WO2008141013A1 (en) 2007-05-08 2008-11-20 Allergan, Inc. S1p3 receptor inhibitors for treating pain
US20100292129A1 (en) 2007-05-24 2010-11-18 Daniel Finley Methods and Compositions for Enhancing Proteasome Activity
TW200914437A (en) 2007-06-20 2009-04-01 Ironwood Pharmaceuticals Inc FAAH inhibitors
EP2018861A1 (en) 2007-07-26 2009-01-28 Laboratorios del Dr. Esteve S.A. 5HT6-Ligands such as sulfonamide derivatives in drug-induced weight-gain
ATE495737T1 (de) 2007-08-01 2011-02-15 Esteve Labor Dr Kombination von mindestens zwei 5-ht6-liganden
CN101778850A (zh) 2007-08-10 2010-07-14 H.隆德贝克有限公司 杂芳基酰胺类似物
JP2009098378A (ja) 2007-10-16 2009-05-07 Olympus Imaging Corp レンズ鏡筒
DE102007051650B4 (de) 2007-10-26 2011-01-05 Eurocopter Deutschland Gmbh Transportrad für einen Hubschrauber
US20100331297A1 (en) 2007-11-07 2010-12-30 Foldrx Pharmaceuticals, Inc. Modulation of protein trafficking
WO2009073620A2 (en) 2007-11-30 2009-06-11 Newlink Genetics Ido inhibitors
WO2009071476A1 (en) 2007-12-04 2009-06-11 F. Hoffmann-La Roche Ag Isoxazolo-pyridine derivatives
GB0723815D0 (en) 2007-12-05 2008-01-16 Glaxo Group Ltd Compounds
WO2009086303A2 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
JP2009179589A (ja) 2008-01-30 2009-08-13 Pharma Ip 抗ウイルス剤
EP2259679A4 (en) 2008-01-31 2011-09-14 Joslin Diabetes Ct METHOD FOR THE TREATMENT OF CALLIQUE CLEANING DISORDERS
WO2009108551A2 (en) 2008-02-25 2009-09-03 H. Lundbeck A/S Heteroaryl amide analogues
PL2247592T3 (pl) 2008-02-25 2012-01-31 Hoffmann La Roche Pirolopirazynowe inhibitory kinazy
JP2011514385A (ja) 2008-03-17 2011-05-06 アラーガン、インコーポレイテッド 炎症を処置するためのｓ１ｐ３受容体阻害剤
BRPI0909183A2 (pt) 2008-03-20 2015-08-25 Forest Lab Holdings Ltd Composto, composição farmacêutica e método de tratamento de condição que responde a inibidor de estearoil-coa dessaturase
BRPI0908603A2 (pt) 2008-03-24 2020-08-18 Novartis Ag inibidores de metaloprotease de matriz com base em arilsulfonamida.
WO2009121033A2 (en) 2008-03-27 2009-10-01 University Of Southern California Substituted nitrogen heterocycles and synthesis and uses thereof
PT2276732E (pt) 2008-04-16 2015-09-28 Karobio Ab Novos ligandos do recetor de estrogénio
US8993574B2 (en) 2008-04-24 2015-03-31 F2G Ltd Pyrrole antifungal agents
GB0808282D0 (en) 2008-05-07 2008-06-11 Medical Res Council Compounds for use in stabilizing p53 mutants
WO2009158371A1 (en) 2008-06-26 2009-12-30 Smithklike Beecham Corporation Inhibitors of akt activity
WO2009158011A1 (en) 2008-06-26 2009-12-30 Amgen Inc. Alkynyl alcohols as kinase inhibitors
EP2141163A1 (de) 2008-07-02 2010-01-06 Bayer Schering Pharma AG Substituierte Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel
US8026271B2 (en) 2008-07-11 2011-09-27 National Health Research Institutes Formulations of indol-3-yl-2-oxoacetamide compounds
EP2323652A2 (en) 2008-08-06 2011-05-25 Summit Corporation Plc Treatment of lysosomal storage disorders and other proteostatic diseases
EP2312949B1 (en) 2008-08-12 2013-08-28 Merck Sharp & Dohme Corp. N-heterocyclic m1 receptor positive allosteric modulators
US8143269B2 (en) * 2008-10-03 2012-03-27 Calcimedica, Inc. Inhibitors of store operated calcium release
US8071605B2 (en) 2008-12-12 2011-12-06 Astrazeneca Ab Piperidine compounds for use in the treatment of bacterial infections
EP2408744A1 (en) 2009-03-18 2012-01-25 Schering Corporation Bicyclic compounds as inhibitors of diacylglycerol acyltransferase
US20120071448A1 (en) 2009-05-05 2012-03-22 Allergan, Inc. S1P3 Receptor Inhibitors for Treating Conditions of the Eye
GB0909441D0 (en) 2009-06-02 2009-07-15 Univ Sheffield Novel indole derivatives
CA2770724A1 (en) 2009-08-10 2011-02-17 Galenea Corporation 5-ht inhibiting indole compounds
WO2011038579A1 (en) 2009-09-30 2011-04-07 Zhejiang Beta Pharma Inc. Compounds and compositions as protein kinase inhibitors
ES2526566T3 (es) 2009-10-19 2015-01-13 Synta Pharmaceuticals Corp. Terapia de combinación contra el cáncer con compuestos inhibidores de HSP90
AU2011210765A1 (en) * 2010-01-28 2012-09-13 President And Fellows Of Harvard College Compositions and methods for enhancing proteasome activity
WO2011127333A2 (en) 2010-04-09 2011-10-13 University Of Louisville Research Foundation, Inc. Compounds for treating disease, for administering, and for pharmaceutical compositions
WO2011133520A1 (en) 2010-04-19 2011-10-27 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
WO2011133521A2 (en) 2010-04-19 2011-10-27 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a vegf inhibitor
US9040703B2 (en) 2010-04-22 2015-05-26 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
WO2011149824A1 (en) 2010-05-24 2011-12-01 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compound and a topoisomerase ii inhibitor
WO2012012712A2 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Tricyclic proteasome activity enhancing compounds
CH703559A2 (de) 2010-08-05 2012-02-15 Christoph Willi Reisegepäck.
AU2011302344B2 (en) 2010-09-13 2015-01-15 Synta Pharmaceuticals Corp. HSP90 inhibitors for treating non-small cell lung cancers in wild-type EGFR and/or KRAS patients
EP2648708A2 (en) 2010-12-08 2013-10-16 Synta Pharmaceuticals Corp. Combination for breast cancer therapy with hsp90 inhibitory compounds
US20130331357A1 (en) 2011-01-11 2013-12-12 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with proteasome inhibitors
ES2734878T3 (es) 2011-02-01 2019-12-12 Univ Illinois Derivados de N-hidroxibenzamida como inhibidores de HDAC y métodos terapéuticos que utilizan los mismos
EP2678013A1 (en) 2011-02-23 2014-01-01 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with radiotherapy
WO2012141796A2 (en) 2011-02-24 2012-10-18 Synta Pharmaceuticals Corp. Prostate cancer therapy with hsp90 inhibitory compounds
US20140045908A1 (en) 2011-02-25 2014-02-13 Synta Pharmaceuticals Corp. Hsp90 inhibitory compounds in treating jak/stat signaling-mediated cancers
WO2012154967A1 (en) 2011-05-12 2012-11-15 Proteostasis Therapeutics, Inc. Proteostasis regulators
WO2012162293A1 (en) 2011-05-23 2012-11-29 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with mek inhibitors
EP2714038A1 (en) 2011-05-24 2014-04-09 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with mtor/pi3k inhibitors
EP2714033A1 (en) 2011-05-26 2014-04-09 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with chk inhibitors
US9260416B2 (en) 2011-05-27 2016-02-16 Amira Pharmaceuticals, Inc. Heterocyclic autotaxin inhibitors and uses thereof
CA2840986A1 (en) 2011-07-07 2013-01-10 Synta Pharmaceuticals Corp. Treating cancer with hsp90 inhibitory compounds
EP2548865B1 (en) 2011-07-22 2014-03-05 Université Joseph Fourier Novel bis-indolic derivatives, their uses in particular as antibacterials
US20140286902A1 (en) 2011-11-02 2014-09-25 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with platinum-containing agents
EP2773345A1 (en) 2011-11-02 2014-09-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
WO2013074594A1 (en) 2011-11-14 2013-05-23 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with braf inhibitors

Also Published As

Publication number Publication date
AU2012253402A1 (en) 2013-05-02
AU2016203895A1 (en) 2016-06-30
ES2724531T3 (es) 2019-09-11
CN103635230B (zh) 2017-10-31
SI2707101T1 (sl) 2019-06-28
US20200299270A1 (en) 2020-09-24
JP6208122B2 (ja) 2017-10-04
CY1121985T1 (el) 2020-10-14
EP2707101A4 (en) 2014-11-26
CA2835610A1 (en) 2012-11-15
CA2835610C (en) 2017-03-14
RS58718B1 (sr) 2019-06-28
HUE044867T2 (hu) 2019-11-28
AU2016203895B2 (en) 2017-12-07
HRP20190867T1 (hr) 2019-07-12
WO2012154967A1 (en) 2012-11-15
CN103635230A (zh) 2014-03-12
EP2707101A1 (en) 2014-03-19
PL2707101T3 (pl) 2019-10-31
US10532996B2 (en) 2020-01-14
US20170247355A1 (en) 2017-08-31
US20120316193A1 (en) 2012-12-13
US9556166B2 (en) 2017-01-31
TR201906779T4 (tr) 2019-05-21
EP2707101B1 (en) 2019-02-13
DK2707101T3 (da) 2019-05-13
JP2014514362A (ja) 2014-06-19
LT2707101T (lt) 2019-05-27
EP3552664A1 (en) 2019-10-16

Similar Documents

Publication Publication Date Title
EP2790561A4 (en) DISHWASHER
EP2755962A4 (en) AZAINDAZOLES
EP2715659A4 (en) ABOUT FEED
PL2882672T3 (pl) Regulator przepływu produktów
EP2754063A4 (en) EXTENSIBILITY OF THE SMB2 PROTOCOL
RS58718B1 (sr) Regulatori proteostaze
EP2723631A4 (en) QUADFOILER
EP2776444A4 (en) dihydropteridinones
AP2014007621A0 (en) 2-Thiopyrimidinones
EP2679138A4 (en) Borescope
EP2695208A4 (en) MICRO-THERMOCOUPLE
EP2708561A4 (en) BIO-PIN
HK1198507A1 (en) Controls
ZA201309244B (en) Current regulator
DK2770906T3 (en) Applanationstonometer
EP2698098A4 (en) campimeter
EP2694655A4 (en) pavec
EP2702929A4 (en) campimeter
GB201100001D0 (en) TidySqueeze2
AU4540P (en) BUNNAN Baloskion tetraphyllum
AU5031P (en) BESYS Beschorneria yuccoides
AU5026P (en) Goldstrike Agapanthus inapertus
AP00723S1 (en) Autorickshaw
AU2011303V (en) Silverado Dianella tasmanica
AU339857S (en) Orchidometer